Astrocyte Announces FDA Clearance of its Investigational NDA for AST-004
Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004
GROTON, Conn.--(BUSINESS WIRE)--Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Progress and Innovation Award from the journal Stroke for authoring one of the journal’s top three publications in 2022. The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”
GROTON, Conn.--(BUSINESS WIRE)--Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers. This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands. nn“Astrocyte is committed to developing innovative therapies that treat brain injuries and improve the lives of patients” nnTweet this nAST-004 is a small molecule adenosine A3/A1 receptor agonist that has consistently shown promising cerebroprotective results in preclinical studies. A Phase 1A study completed in 2022 with single ascending 10-minute bolus doses of AST-004 showed no significant adverse effects or safety signals. The Phase 1B study will assess the safety, tolerability, and pharmacokinetics and pharmacodynamics of AST-004 administered as a loading dose followed by a continuous infusion over 6 hours, and provide important data to support the company’s future Phase 2 program. nn“Astrocyte is committed to developing innovative therapies that treat brain injuries and improve the lives of patients,” said Lisa Manna, Astrocyte’s Vice President of Clinical Development Operations. “The initiation of this Phase 1B study is an important step forward in the development of AST-004 supporting multiple indications, and we look forward to continuing the clinical development of this novel and promising therapy.” nnThe study is funded in part by the Medical Technology Enterprise Consortium (MTEC) in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) of the United States of America Department of Defense. nnFor more information on Astrocyte Pharmaceuticals and the AST-004 program, please visit www.astrocytepharma.com. nnAbout Astrocyte Pharmaceuticals Inc. nnAstrocyte Pharmaceuticals Inc. is a privately held, clinical-stage, drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the cerebroprotective benefits of enhancing astrocyte function, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, traumatic brain injury, concussion, and neurodegenerative disorders such as Alzheimer’s disease. For more information, please visit us at Astrocyte Pharmaceuticals Inc.
GROTON, Conn.--(BUSINESS WIRE)--Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.